INAB News

The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more

IN8bio, a Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies, raised $40 million by offering 4 million shares at $10, the low end of the range of $10 to $12. The company's pipeline contains lead candidates INB-200, which is currently in a Phase 1 trial for newly diagnosed glioblastoma, and INB-100, which is currently in a Phase 1 trial for patients with...read more

Updated Monday, 7/26. After another week of record activity, the IPO market is expected to remain hot with 25 IPOs scheduled for the week ahead. If all scheduled IPOs begin trading as expected, it would be the busiest week for the US IPO market in more than two decades. Long-awaited retail brokerage Robinhood Markets (HOOD) plans to raise $2.2...read more

IN8bio, a Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $44 million by offering 4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, IN8bio would command a fully diluted market value of $215 million. IN8bio originally planned to...read more